aTyr Pharma announced a corporate restructuring involving an approximately 60% workforce reduction to conserve capital and prioritize its lead asset, efzofitimod, for interstitial lung disease. The company expects these measures to reduce annualized operating expenses by $13 million starting in Q4 2026. Key executive changes include CFO Jill Broadfoot stepping down on September 30, 2026, with VP Brandon Yaras succeeding her on October 1, 2026; General Counsel Nancy Denyes also steps down as a consultant. Financially, the company held $58.9 million in cash and investments at June 30, 2026, providing a runway into late 2028. The firm submitted a Phase 3 protocol for efzofitimod in pulmonary sarcoidosis to the FDA in June 2026 and awaits feedback by August 2026. Enrollment is complete in the Phase 2 EFZO-CONNECT study for SSc-ILD, with top-line results expected in Q1 2027. aTyr Pharma operates as a clinical-stage biotechnology company focused on discovering therapies from its proprietary tRNA synthetase platform.

aTyr Pharma, Inc. entered into a termination agreement with Kyorin Pharmaceutical Co., Ltd., effective July 30, 2026, mutually ending their collaboration and license agreement for efzofitimod in Japan. This action reverts exclusive rights to develop and commercialize the drug globally to aTyr Pharma. The parties also terminated associated ancillary agreements and established wind-down procedures, including the transfer of clinical data and regulatory filings from Kyorin to aTyr. No outstanding payments were due between the entities. aTyr Pharma is a biopharmaceutical company focused on developing therapies for rare diseases.

aTyr Pharma, Inc. received an extension from Nasdaq to regain compliance with the minimum bid price requirement, extending the compliance deadline to November 30, 2026. The company has indicated its intention to effect a reverse stock split if necessary to resolve the deficiency.